Loading...
NPI 1982610267 · Las Vegas, NV · Cardiovascular Disease Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Stephen Savran is a cardiovascular disease physician provider located in Las Vegas, Nevada. This profile covers 10 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Stephen Savran |
| Address | 3150 N Tenaya Way |
| City | Las Vegas |
| State | NV |
| ZIP | 89128 |
| Taxonomy | Cardiovascular Disease Physician |
| NPI Enumerated | July 31, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.4M |
| Medicaid | $320 |
This provider’s procedure mix is concentrated in advanced cardiac imaging and nuclear cardiology: high-volume PET myocardial perfusion studies (codes 78492 and 78431) combined with radiopharmaceutical supply codes (A9555, A9526) and pharmacologic stress agent use (J2785) point to an operation centered on myocardial perfusion PET and stress testing rather than general cardiology office visits. The presence of CT-based cardiac codes (75574, 75571) and frequent ECG/stress monitoring (93015, 93010) further supports a service-line oriented around diagnostic cardiac imaging and stress evaluation.
Medicare revenue is heavily concentrated in a few high-revenue imaging codes: 78492 ($644.7K, 26.7%), 78431 ($558.5K, 23.2%) and A9555 ($484.8K, 20.1%) together account for 70.0% of the provider’s total Medicare revenue, indicating reliance on a narrow set of PET/nuclear imaging services to drive most Medicare income. This concentration suggests that changes in reimbursement or utilization for these specific PET imaging codes would materially affect overall Medicare revenue.
Medicaid activity is effectively limited to routine ECG interpretation: code 93010 accounts for 100.0% of the provider’s total Medicaid revenue, with 83 claims and $332 in lifetime Medicaid revenue reported. At $4 average paid/claim and a Medicaid total of $320, the provider’s Medicaid footprint is negligible compared with Medicare and appears focused on low-revenue ECG interpretation when it occurs.
The provider is overwhelmingly Medicare-facing: lifetime Medicare revenue is $2.4M versus just $320 in Medicaid revenue, making Medicare the dominant payer by scale and indicating this is effectively a single-payer (Medicare) practice for meaningful revenue. Analysts should treat Medicaid exposure as immaterial to network or payer-strategy considerations for this NPI.
Several Medicare codes show highly atypical national standing, marking the provider as a major outlier in specific nuclear cardiology services: 78492 ranks #18 of 926 (98th percentile; extreme outlier, far above typical national volume for this code), A9555 ranks #14 of 1266 (99th percentile; notably above typical national volume for this code), and J2785 ranks #11 of 6388 (100th percentile; extreme outlier, far above typical national volume for this code). At the same time, 78431 ranks #39 of 1377 (97th percentile; typical, unremarkable volume for this code), indicating that while some PET services are unusually concentrated here, others are closer to peer norms.
High claim counts for ancillary and support codes reinforce the imaging-center profile: J2785 has 3.8K claims with $159.9K revenue and is labeled a 100th percentile extreme outlier, and 93015 shows 950 claims with $52.3K revenue and ranks #13 of 7716 (100th percentile; extreme outlier, far above typical national volume for this code). These volumes imply sustained throughput of stress studies and routine supervised stress testing, consistent with a dedicated imaging/stress lab operational model.
The provider has a long tenure in the Medicare program, with NPI enumerated 2006-07-31 (~20 years ago), which combined with the concentrated, high-volume imaging profile suggests an established specialty practice or imaging center footprint rather than a recent entrant or general cardiology clinician. This longevity strengthens the interpretation that the current coding mix reflects stable service offerings and operational specialization.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78492 | In this diagnostic procedure, the provider performs a myocardial perfusion PET imaging study which means it reveals the flow of oxygenated blood to the heart muscles. The service also includes… | 570 | $1,140 | $644.7K |
| 78431 | The provider performs a PET myocardial imaging scan, a type of nuclear imaging test, with CT transmission scan that reveals blood flow to and from the heart (perfusion). Ejection fraction and… | 390 | $1,450 | $558.5K |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 1,200 | $400 | $484.8K |
| A9526 | Nitrogen n-13 ammonia, diagnostic, per study dose, up to 40 millicuries | 700 | $590 | $410.7K |
| J2785 | Injection, regadenoson, 0.1 mg | 3,810 | $40 | $159.9K |
| 78434 | The provider performs a positron emission tomography (PET) study at both rest and stress to measure myocardial blood flow. Stress is induced by injection of a drug. Report this code in conjunction… | 780 | $110 | $81.4K |
| 93015 | The provider supervises the recording of the electrical activity of the heart to examine any abnormality in its functioning by obtaining blood pressure and electrocardiograph readings at regular… | 950 | $60 | $52.3K |
| 75574 | The provider uses computed tomography (CT) with instillation of contrast to examine any defect or abnormality in the heart or coronary artery or any abnormality due to an already present bypass… | 70 | $230 | $15.7K |
| 75571 | The provider uses computed tomography (CT) for quantitative measurement of calcium deposit in the coronary vessels of heart. She does not administer contrast during the procedure. | 30 | $80 | $2.4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 8,400 | $0 | $0 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 10 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 93010 | The provider interprets and reports on the results of a routine 12–lead (or more) electrocardiogram. | 80 | $1 | $330 |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 93010 | The provider interprets and reports on the results of a routine 12–lead (or more) electrocardiogram. | 145 | 210 | 200 | $1 | $21.9K |
Other providers in the same ZIP code as Stephen Savran, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.